After receiving formal permission, bedaquiline and delamanid have been used to treat patients having multidrug-resistant/rifampicin-resistant tuberculosis from September 1, 2016. Researchers wanted to examine and contrast the ultimate treatment outcomes of patients who got bedaquiline vs. those who received delamanid. A study of patients with multidrug-resistant/rifampicin-resistant tuberculosis received bedaquiline or delamanid from September 1, 2016, to February 28, 2018. According to the initial medicine taken, patients were divided into two groups: bedaquiline and delamanid. The final treatment outcomes were analyzed and compared between the groups. Two-hundred sixty patients with multidrug-resistant/rifampicin-resistant tuberculosis were included in the final analysis, out of which 119 (45.8%) and 141 (54.2%) were assigned to the bedaquiline and delamanid groups, respectively. Thirty patients (11.5%) showed increased resistance to second-line injectable medicines, 94 patients (36.2%) showed additional resistance to fluoroquinolones, and 37 patients (14.2%) showed resistance to both. The overall effectiveness rate of the treatment was 79.2%. Treatment success was not linked with starting bedaquiline instead of delamanid (adjusted odds ratio, .671; 95% confidence interval,.350–1.285). The two groups did not have statistically different rates of adverse events. In patients with multidrug-resistant/rifampicin-resistant tuberculosis, the initial choice of bedaquiline or delamanid made no difference in the end treatment outcome or the frequency of side events.